Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

f 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard in the first half of 2009; data from the celgosivir Phase II extension protocol being available by the end of 2007; 4-week interim results from the Phase II viral kinetics combination study of celgosivir in approximately 10 treatment-naive patients in October 2007; submitting an IND in the US in the first quarter of 2008 for the future development of celgosivir; Cutanea Life Sciences completing the Phase II CLS001 rosacea clinical trial in 2007; our estimate of the probable royalties payable to the holders of the convertible royalty participation units; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $11 million to $13 million; and the Company's financial resources being sufficient to fund operations into the third quarter of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; our ability to manage licensing opportunities; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; our partner Cutanea Life Sciences completing a Phase II CLS001 rosacea clinical trial in 2007; to and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on c
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... Whitehouse Laboratories has formally announced a ... and Package Test Capacity. Responding to growing demands from ... increase in environmental chamber storage space that will enable ... samples to be securely held on site at Whitehouse ... has already taken place with the recent completion of ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... one of the key challenges in the development of ... physicists. , In a paper published today (28 October) ... colleagues show how to make a new type of ... devices, such as high-precision sensors and specialised superfast computers, ... But the methods for trapping these tiny particles are ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... 21, 2011 GeneLink, Inc. (OTCBB: GNLK.OB, ... company, reported financial results for the quarter ended September ... Chairman and CEO stated, "From a business development potential, ... in the history of the Company.  The Company continues ...
... The report " Leukemia Therapeutics ... Assessment & Global Market Forecast (2010 - 2020) ... restraints, and opportunities in North America, & Europe. ... TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & ...
... November 18, 2011 Percentage of revenues ... to medical relief organization building a hospital in Ethiopia ... scientific, technical and medical information products and services, announced ... Aid (ICA) through its "Pillars of Hope" ...
Cached Biology Technology:GeneLink Marketing Efforts Poised to Show Results 2GeneLink Marketing Efforts Poised to Show Results 3MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3
(Date:10/30/2014)... This news release is available in German . ... we as individuals prompt our fellow humans to behave ... to social dilemmas in game theory. Previous studies assumed ... large groups. Nonetheless, scientists from the Max Planck Institute ... us can exert an influence on the cooperative behaviour ...
(Date:10/30/2014)... Biological membranes are mainly composed of lipid bilayers. ... ions onto lipid membranes helps clarify functional processes ... a quantitative description of the equilibria between lipid ... Zbigniew Figaszewski from the University of Bialystok, Poland, ... findings, just published in EPJ E . ...
(Date:10/29/2014)... to date, researchers have used DNA sequencing to uncover ... Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount ... of Harvard and MIT, and their colleagues examined more ... unrelated people. They identified changes in 107 genes that ... spectrum disorder (ASD) – a jump from the nine ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Ion adsorption matter in biology 2
... patients whose lungs are implanted with a pencil ... of lung function and report better quality of ... Frank C. Sciurba, M.D., reported today at CHEST ... of Chest Physicians. Scientific sessions continue through Thursday, ...
... home residents contract pneumonia, it is a blow to their ... Jean Mayer USDA Human Nutrition Research Center on Aging at ... concentration in the blood may help reduce the risk of ... data, it appears that daily zinc intake can help nursing ...
... activity in overweight children improves their thinking and reduces ... 200 overweight, inactive children ages 7-11 also showed that ... bone density. Is exercise a magic wand ... are still overweight but less so, with less fat, ...
Cached Biology News:Endobronchial valve significantly improves emphysema 2Zinc may reduce pneumonia risk in nursing home elderly 2Exercise improves thinking, reduces diabetes risk in overweight children 2Exercise improves thinking, reduces diabetes risk in overweight children 3
... to the third cytoplasmic loop of human ... KLH. The immunizing peptide has 79% homology ... Physical form: Solution in phosphate buffered saline, ... Titertest method: IHC (p). Titertest values: ...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... 5 Fluorescein 6-Fam, Hex, Tet ... Fluorescein Tamra Black Hole Quenchers ... Hex, Tet Tamra, Joe 3 ... Institute, New York Double labelled probes are ...
Biology Products: